Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Rheumatology | Musculoskeletal | Orthopedics/Orthopedic Surgery
Ankylosing Spondylitis Clinical Trials
A listing of Ankylosing Spondylitis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Mesa : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
California
Fair Oaks : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
La Jolla : University of California, San Diego
OTIS Autoimmune Diseases in Pregnancy Project
Upland : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Georgia
Alpharetta : CSI Research Inc
A Phase III, randomized, double-blind, placebo-controlled trial in patients with Ankylosing Spondylitis (AS).
Maryland
Wheaton : The Center for Rheumatology and Bone Research
A randomized double blind placebo controlled dose ranging study to evaluate the efficacy and safety of IL-6Ra mAb in patients with Ankylosing Spondylitis
Minnesota
Edina : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Mississippi
Tupelo : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Nebraska
Omaha : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Oklahoma
Oklahoma City : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Pennsylvania
Duncansville : Altoona Center for Clinical Research Updated
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
Duncansville : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
South Carolina
Charleston : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Tennessee
Jackson : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Knoxville : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Texas
Mesquite : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Austria
Graz : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Neudorf : Site Reference ID/Investigator# 69645
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients`Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Wien : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Belgium
Brussels : Erasme University Hospital
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Diepenbeek : Limburg University Centre
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Gent : Universitair Ziekenhuis, Afdeling Rheumatologie
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Leuven : University Hospital Leuven
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Canada
Brampton : Site Reference ID/Investigator# 54758 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Brockville : Site Reference ID/Investigator# 65502 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Burlington : Site Reference ID/Investigator# 54764 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Burlington : Site Reference ID/Investigator# 67347 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Calgary : Site Reference ID/Investigator# 64274 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
View More »
Cranbrook : Site Reference ID/Investigator# 55242 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Fredericton : Site Reference ID/Investigator# 55256 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Fredericton : Site Reference ID/Investigator# 54748 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Hamilton : Site Reference ID/Investigator# 55417 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Hamilton : Site Reference ID/Investigator# 65011 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Hamilton : Site Reference ID/Investigator# 54762 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Kamloops : Site Reference ID/Investigator# 54577 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Kitchener : Site Reference ID/Investigator# 70093 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Laval : Site Reference ID/Investigator# 54576 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Milton : Site Reference ID/Investigator# 81877 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Mississauga : Site Reference ID/Investigator# 55401 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Mississauga : Site Reference ID/Investigator# 54581 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Mississauga : Site Reference ID/Investigator# 54750 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Montreal : Site Reference ID/Investigator# 54754 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Montreal : Site Reference ID/Investigator# 54761 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Montreal : Site Reference ID/Investigator# 63655 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Nepean : Site Reference ID/Investigator# 55410 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Ottawa : Site Reference ID/Investigator# 55296 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Outremont : Site Reference ID/Investigator# 54574 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Owen Sound : Site Reference ID/Investigator# 54583 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Penticton : Site Reference ID/Investigator# 67096 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Pointe-Claire : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Prince George : Site Reference ID/Investigator# 55227 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Quebec City : Site Reference ID/Investigator# 45623 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Quebec City : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Rimouski : Site Reference ID/Investigator# 54765 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Sainte-Foy : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
St. Catharines : Site Reference ID/Investigator# 67282 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
St. John's : Site Reference ID/Investigator# 54757 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
St-Leonard : Site Reference ID/Investigator# 55460 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Toronto : Site Reference ID/Investigator# 54751 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Toronto : Site Reference ID/Investigator# 55411 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Toronto : Site Reference ID/Investigator# 55449 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Toronto : Site Reference ID/Investigator# 54575 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Trois-Rivieres : Site Reference ID/Investigator# 55469 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Vancouver : Site Reference ID/Investigator# 54572 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Victoria : Site Reference ID/Investigator# 55197 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Winnipeg : Site Reference ID/Investigator# 54580 Updated
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Winnipeg : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Czech Republic
Brno : Site Reference ID/Investigator# 63774
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bruntal : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Kromeriz : Site Reference ID/Investigator# 63775
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Ostrava : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Ostrava : Site Reference ID/Investigator# 63769
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
View More »
Pardubice : Site Reference ID/Investigator# 63772
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Praha 2 : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Uherske Hradiste : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Estonia
Tallinn : Site Reference ID/Investigator# 71617
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Tallinn : Site Reference ID/Investigator# 71616
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Tartu : Site Reference ID/Investigator# 71618
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Finland
Helsinki : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Helsinki : University Central Hospital, Division of Rheumatology
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
HUS : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Hyvinkää : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Jyvaskyla : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
View More »
Seinajoki : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
France
Paris : Groupe Hopitalier Cochin
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Paris : Universitat R. Descartes, Hopital Cochin
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Germany
Berlin : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Berlin : Charite Klinikum Steglitz
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Berlin : Charite Mitte
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Berlin : Charité University Medicine Berlin, Campus Benjamin-Franklin
Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
Berlin : Pfizer Investigational Site Updated
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
View More »
Herne : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Herne : Rheumazentrum Ruhrgebiet
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Herne : Rheumazentrum Ruhrgebiet
Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
München : Ludwigs-Maximilian-Universität
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Würzburg : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Hungary
Budapest : Site Reference ID/Investigator# 65210
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Budapest : Site Reference ID/Investigator# 49883
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Budapest : Site Reference ID/Investigator# 65206
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Debrecen : Site Reference ID/Investigator# 65208
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Debrecen : Site Reference ID/Investigator# 65224
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
View More »
Eger : Site Reference ID/Investigator# 65205
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Esztergom : Site Reference ID/Investigator# 65222
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Gyor : Site Reference ID/Investigator# 65207
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Gyula : Site Reference ID/Investigator# 65223
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Heviz : Site Reference ID/Investigator# 65225
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kecskemet : Site Reference ID/Investigator# 65203
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kistarcsa : Site Reference ID/Investigator# 65209
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Miskolc : Site Reference ID/Investigator# 65214
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Nyiregyhaza : Site Reference ID/Investigator# 65211
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Pecs : Site Reference ID/Investigator# 65221
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Szeged : Site Reference ID/Investigator# 65204
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Szekesfehervar : Site Reference ID/Investigator# 65227
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Szombathely : Site Reference ID/Investigator# 65213
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Veszprem : Site Reference ID/Investigator# 65202
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Italy
Bergamo : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Catania : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Torino : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Valeggio Sul Mincio : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Japan
Aichi : Site Reference ID/Investigator# 68725
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Aichi : Site Reference ID/Investigator# 64970
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Aichi : Site Reference ID/Investigator# 59603
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Aichi : Site Reference ID/Investigator# 59605
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Akita : Site Reference ID/Investigator# 54989
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
View More »
Aomori : Site Reference ID/Investigator# 51171
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Asahikawa : Site Reference ID/Investigator# 54715
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Bunkyo-ku, Tokyo : Site Reference ID/Investigator# 51089
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chiba : Site Reference ID/Investigator# 51095
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chiba : Site Reference ID/Investigator# 51096
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chiba : Site Reference ID/Investigator# 54720
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chuo : Site Reference ID/Investigator# 54991
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fujieda : Site Reference ID/Investigator# 79755
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 51164
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 51166
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 51168
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 51163
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 80934
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 55016
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 51165
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 51124
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Reference ID/Investigator# 51114
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukushima : Site Reference ID/Investigator# 51086
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gifu : Site Reference ID/Investigator# 54709
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gifu : Site Reference ID/Investigator# 51183
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gifu : Site Reference ID/Investigator# 59585
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gyoda : Site Reference ID/Investigator# 79756
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hamamatsu : Site Reference ID/Investigator# 54816
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hannan : Site Reference ID/Investigator# 79773
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hirakata : Site Reference ID/Investigator# 51189
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hirosaki : Site Reference ID/Investigator# 51147
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Reference ID/Investigator# 55015
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Reference ID/Investigator# 51127
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Reference ID/Investigator# 54983
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Reference ID/Investigator# 79754
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Reference ID/Investigator# 51155
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Reference ID/Investigator# 51162
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Reference ID/Investigator# 51126
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hokkaido : Site Reference ID/Investigator# 51122
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hokkaido : Site Reference ID/Investigator# 54987
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hyogo : Site Reference ID/Investigator# 64968
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hyogo : Site Reference ID/Investigator# 51195
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hyogo : Site Reference ID/Investigator# 54822
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ichikawa : Site Reference ID/Investigator# 54713
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ichinoseki : Site Reference ID/Investigator# 79758
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ikoma : Site Reference ID/Investigator# 64934
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Isahaya : Site Reference ID/Investigator# 59607
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Iwafune : Site Reference ID/Investigator# 51088
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Izumo : Site Reference ID/Investigator# 59593
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Izumo : Site Reference ID/Investigator# 51160
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Izunokuni : Site Reference ID/Investigator# 51190
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Izunokuni : Site Reference ID/Investigator# 51187
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Joetsu : Site Reference ID/Investigator# 84018
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Joetsu : Site Reference ID/Investigator# 84019
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kaga : Site Reference ID/Investigator# 79759
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kagoshima : Site Reference ID/Investigator# 55021
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kagoshima : Site Reference ID/Investigator# 67172
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kagoshima : Site Reference ID/Investigator# 55020
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanagawa : Site Reference ID/Investigator# 54712
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Reference ID/Investigator# 64948
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Reference ID/Investigator# 64936
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Reference ID/Investigator# 55008
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Reference ID/Investigator# 55009
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kashihara : Site Reference ID/Investigator# 71474
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kashihara : Site Reference ID/Investigator# 67171
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kasugai : Site Reference ID/Investigator# 75096
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kasugai : Site Reference ID/Investigator# 75099
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawagoe : Site Reference ID/Investigator# 51152
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawagoe : Site Reference ID/Investigator# 51117
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawasaki : Site Reference ID/Investigator# 51188
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawasaki : Site Reference ID/Investigator# 75095
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kitakyushu : Site Reference ID/Investigator# 59588
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kitakyushu : Site Reference ID/Investigator# 51167
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Reference ID/Investigator# 54725
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Reference ID/Investigator# 54982
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Reference ID/Investigator# 54724
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Reference ID/Investigator# 59601
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Koshigaya : Site Reference ID/Investigator# 51120
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kudamatsu : Site Reference ID/Investigator# 51158
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kumamoto : Site Reference ID/Investigator# 59586
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kurashiki : Site Reference ID/Investigator# 51170
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kurashiki : Site Reference ID/Investigator# 54723
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kurume : Site Reference ID/Investigator# 55017
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 51119
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 51157
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 55010
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 51198
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 64994
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 51118
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 51156
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 51161
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 64933
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Reference ID/Investigator# 55011
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Maebashi : Site Reference ID/Investigator# 51087
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Maebashi : Site Reference ID/Investigator# 54990
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Maizuru : Site Reference ID/Investigator# 79753
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Matsuyama : Site Reference ID/Investigator# 49884
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Minato : Site Reference ID/Investigator# 51154
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Minato : Site Reference ID/Investigator# 51151
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Miyazaki : Site Reference ID/Investigator# 67173
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagakute : Site Reference ID/Investigator# 64967
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagakute : Site Reference ID/Investigator# 59591
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagakute : Site Reference ID/Investigator# 51169
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagano : Site Reference ID/Investigator# 51153
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagano : Site Reference ID/Investigator# 54992
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagano : Site Reference ID/Investigator# 59608
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagaokakyo : Site Reference ID/Investigator# 64931
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagasaki : Site Reference ID/Investigator# 51123
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Reference ID/Investigator# 51182
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Reference ID/Investigator# 75097
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Reference ID/Investigator# 59584
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Reference ID/Investigator# 54985
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Reference ID/Investigator# 54821
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Reference ID/Investigator# 54819
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Reference ID/Investigator# 59600
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nara : Site Reference ID/Investigator# 51186
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Niigata : Site Reference ID/Investigator# 54814
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nirasaki : Site Reference ID/Investigator# 84020
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nishinomiya : Site Reference ID/Investigator# 55004
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nisshin : Site Reference ID/Investigator# 84194
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Obihiro : Site Reference ID/Investigator# 75094
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Obihiro : Site Reference ID/Investigator# 59604
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Oita : Site Reference ID/Investigator# 59598
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Oita : Site Reference ID/Investigator# 55019
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Okayama : Site Reference ID/Investigator# 59606
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Okayama : Site Reference ID/Investigator# 55013
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ono : Site Reference ID/Investigator# 84022
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 54820
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51194
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 54716
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51191
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 55002
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51149
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 59602
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51196
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 59590
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51113
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 54984
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 64932
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51197
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 55001
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 64935
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51192
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51173
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51185
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51150
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Reference ID/Investigator# 51125
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaki : Site Reference ID/Investigator# 51083
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Otsu : Site Reference ID/Investigator# 55012
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Otsu : Site Reference ID/Investigator# 64938
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Saga : Site Reference ID/Investigator# 55018
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sagamihara : Site Reference ID/Investigator# 54818
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Saitama : Site Reference ID/Investigator# 54997
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sakai : Site Reference ID/Investigator# 84021
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Reference ID/Investigator# 59597
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Reference ID/Investigator# 51085
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Reference ID/Investigator# 51084
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Reference ID/Investigator# 54988
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sayama : Site Reference ID/Investigator# 51097
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sendai : Site Reference ID/Investigator# 51116
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sendai : Site Reference ID/Investigator# 51148
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Takamatsu : Site Reference ID/Investigator# 54710
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Takatsuki : Site Reference ID/Investigator# 55003
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Takatsuki : Site Reference ID/Investigator# 51193
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tenri : Site Reference ID/Investigator# 54726
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tochigi : Site Reference ID/Investigator# 59592
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokorozawa : Site Reference ID/Investigator# 54986
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51093
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 64937
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54721
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54995
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 71476
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54815
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54994
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54996
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51091
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 68726
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51146
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54711
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54717
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51129
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 79757
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51082
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51172
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51094
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54993
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51115
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51121
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51092
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51174
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 51090
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54722
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 54718
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Reference ID/Investigator# 59587
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tomakomai : Site Reference ID/Investigator# 59596
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Reference ID/Investigator# 59599
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Reference ID/Investigator# 55007
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Reference ID/Investigator# 64996
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Reference ID/Investigator# 55005
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Reference ID/Investigator# 55006
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Reference ID/Investigator# 51128
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Reference ID/Investigator# 59589
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyoake : Site Reference ID/Investigator# 64995
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyohashi : Site Reference ID/Investigator# 80918
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tsukuba : Site Reference ID/Investigator# 59594
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tsuyama : Site Reference ID/Investigator# 71475
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Urayasu : Site Reference ID/Investigator# 54714
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Wakayama : Site Reference ID/Investigator# 54817
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yamaguchi : Site Reference ID/Investigator# 64969
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yamaguchi : Site Reference ID/Investigator# 51159
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yamaguchi : Site Reference ID/Investigator# 54823
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Reference ID/Investigator# 80933
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Reference ID/Investigator# 59595
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Reference ID/Investigator# 54999
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Reference ID/Investigator# 55000
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Reference ID/Investigator# 54998
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Reference ID/Investigator# 75098
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yonago : Site Reference ID/Investigator# 55014
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Korea, Republic of
Seoul : Hanyang University Hospital for rheumatic disease
The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection
Netherlands
Amsterdam : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Amsterdam : Academic Ziekenhuis
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Amsterdamn : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Haarlem : Merck Sharp & Dohme BV
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012 AM1)
Maastricht : University Hospital Maastricht
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
View More »
Utrecht : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Norway
Lillehammer : Lillehammer Hospital for Rheumatic Diseases
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
Romania
Brasov : Site Reference ID/Investigator# 66394
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Brasov : Site Reference ID/Investigator# 66393
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 93741
Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
Bucharest : Site Reference ID/Investigator# 100195
Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
Bucharest : Site Reference ID/Investigator# 66365
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
View More »
Bucharest : Site Reference ID/Investigator# 66364
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 66375
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 66376
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 69389
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 66377
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 66366
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 66378
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 69661
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Reference ID/Investigator# 90253
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Constanta : Site Reference ID/Investigator# 66398
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Craiova : Site Reference ID/Investigator# 66390
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Craiova : Site Reference ID/Investigator# 88633
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Craiova : Site Reference ID/Investigator# 69390
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Craiova : Site Reference ID/Investigator# 66389
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Deva : Site Reference ID/Investigator# 66403
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Deva : Site Reference ID/Investigator# 66402
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Iasi : Site Reference ID/Investigator# 66384
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Iasi : Site Reference ID/Investigator# 66386
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Iasi : Site Reference ID/Investigator# 66387
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Iasi : Site Reference ID/Investigator# 66385
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Ploiesti : Site Reference ID/Investigator# 66405
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Sibiu : Site Reference ID/Investigator# 66397
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Sibiu : Site Reference ID/Investigator# 66400
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Targu-Mures : Site Reference ID/Investigator# 66391
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Timisoara : Site Reference ID/Investigator# 66383
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Russian Federation
Ekaterinburg : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Korolev : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Moscow : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Moscow : Site Reference ID/Investigator# 94619
Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
Petrozavodsk : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
View More »
Sankt-Peterburg : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
St-Petersburg : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Tula : Site Reference ID/Investigator# 94629
Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
Yaroslavl : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Singapore
Singapore : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Slovakia
Banska Bystrica : Site Reference ID/Investigator# 64342
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kosice : Site Reference ID/Investigator# 64343
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Piestany : Site Reference ID/Investigator# 65732
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Piestany : Site Reference ID/Investigator# 65733
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Spain
El Palmar : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
La Coruna : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Madrid : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Sabadell : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Santander : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Switzerland
Basel : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Fribourg : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Zuerich : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Ukraine
Kharkov : Site Reference ID/Investigator# 70696
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kiev : Site Reference ID/Investigator# 70693
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kryvyi Rih : Site Reference ID/Investigator# 74136
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Odesa : Site Reference ID/Investigator# 74135
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Simferopol : Site Reference ID/Investigator# 74833
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
View More »
Zhytomyr : Site Reference ID/Investigator# 91913
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
United Kingdom
Cambridge : University of Cambridge/ Clin Med
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Leeds : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Leeds : University of Leeds
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
London : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
London : Novartis Investigative Site
Efficacy at 16 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Ankylosing Spondylitis (AS)
View More »
Norwich : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Torquay : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Yeovil : Novartis Investigative Site Updated
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
